Business, energy, technology, markets and global industry news from Business News Today

petrelintide

PharmaDeviceNews petrelintide
Infographic summarizing positive Phase 2 petrelintide results in obesity and type 2 diabetes, highlighting up to 9.2% weight loss, improved glycemic control, low gastrointestinal discontinuation, and a roughly 7,000-patient Phase 3 program.
Pharma & Biotech

Can Roche’s petrelintide challenge GLP-1 drugs after strong obesity and diabetes data?

Zealand Pharma and Roche have reported positive Phase 2 data for petrelintide in people with obesity and type 2 diabetes, combining up to 9.2% weight loss with improved glycemic control and a low gastrointestinal discontinuation rate as the amylin therapy enters a roughly 7,000-patient Phase 3 program.

Read More
Genentech’s $2 billion Holly Springs manufacturing facility is taking shape as Roche builds U.S. production capacity for future metabolic and obesity medicines. Representative image.
Pharma & Biotech

Genentech’s $2bn Holly Springs bet is taking shape, but the hardest manufacturing work is still ahead

Genentech’s $2 billion Holly Springs plant reaches a key milestone as Roche builds U.S. manufacturing capacity for future metabolic medicines.

Read More
Representative image: Genentech’s obesity drug data update at ADA 2026 underscores rising interest in enicepatide, petrelintide and next-generation weight management therapies.
Pharma & Biotech

Can enicepatide and petrelintide help Genentech build a differentiated obesity franchise?

Genentech advances enicepatide and petrelintide obesity data at ADA 2026. Find out why Roche’s strategy matters now.

Read More
Pharma & Biotech

Zealand Pharma advances petrelintide toward Phase 3 as obesity treatment competition intensifies

Zealand Pharma advances petrelintide toward Phase 3 after strong Phase 2 obesity trial results. Discover what this means for the evolving weight-loss drug market.

Read More